FDA
-
-
-
-
-
-
-
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
-
-
-
-
-
-
-
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
-
-
-
-
-
-
-
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
-
-
-
-
-
-
-
BioVie completes $12 million public offering on NASDAQ
-
-
-
-
-
-
-
BioVie names Amy Chappell and Kameel Farag to board of directors
-
-
-
-
-
-
-
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
-
-
-
-
-
-
-
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial
-
328,685 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

